Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

PEI Province Implements Biosimilar Switching Policy

Oct 12, 2023

Prince Edward Island announced implementation of a biosimilar switching policy consistent with ten other provinces in Canada.  From 12 October 2023, patients covered under PEI Pharmacare program will begin switching biosimilars. Pharmacare beneficiaries will have until 30 June 2024 to work with healthcare providers to switch to a biosimilar.  Patients currently using Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade® or Rituxan® will be transitioned to a biosimilar version by 30 June 2024 to maintain their coverage.

We reported on previous Canadian announcements of Biosimilar switching initiatives, including Newfoundland and LabradorYukon, Ontario, British ColumbiaAlbertaNew BrunswickQuebec, Northwest Territories, Nova Scotia and Saskatchewan.